Clinical Trials Logo

Cocaine-Related Disorders clinical trials

View clinical trials related to Cocaine-Related Disorders.

Filter by:

NCT ID: NCT00223236 Completed - Cocaine Dependence Clinical Trials

Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence

Start date: July 2010
Phase: Phase 3
Study type: Interventional

The purpose of this research is to determine if a citicoline supplement is associated with a reduction in cocaine use and craving in patients with bipolar disorder (a mental disorder marked by alternating periods of mania and depression) or schizoaffective disorder/bipolar type (a psychotic disturbance in which there is a mixture of schizophrenic and manic-depressive symptoms) and cocaine abuse/dependence. This research also wants to explore if citicoline supplements are associated with greater improvement in symptoms of mania and on memory and cognition (the mental faculty of perception, reasoning, and judgement) in these patients.

NCT ID: NCT00223210 Completed - Bipolar Disorder Clinical Trials

An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence

Start date: November 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if quetiapine add-on therapy is associated with a decrease in cocaine use and craving and a greater improvement in mood.

NCT ID: NCT00218660 Completed - Alcoholism Clinical Trials

Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1

Start date: April 1998
Phase: Phase 3
Study type: Interventional

The purpose of this study is to see whether naltrexone is safe and useful in preventing alcohol relapse, as well as in decreasing craving for alcohol in people with a diagnosis of alcohol and cocaine dependence. Naltrexone is approved by the Food and Drug Administration (FDA) for the treatment of alcohol dependence. However, the medication was not approved as yet at the dosage we will use in this study. The dosage we will use for the study (150 mg), is greater than the recommended dosage from the Physician's Desk Reference (50mg). Unlike other medicines (like Antabuse) useful in the treatment of alcohol dependence, naltrexone will not make you sick if you drink alcohol. Rather, people who are taking this medication have reported that it helps decrease the pleasure associated with drinking for them. This study is being conducted because the medication (Naltrexone) has not been well studied in people with both alcohol and cocaine dependence, so it is still investigational. We believe that if we can reduce alcohol consumption through naltrexone and psychotherapy, this may lead to reduced cocaine use. We are also conducting this study to test two different types of psychotherapy as a method for reducing cocaine and alcohol use. One type of psychotherapy, CBT, is designed to help people learn to cope with situations that put them at high risk for relapse to cocaine and/or alcohol use. The other type of psychotherapy, BRENDA, will use focuses on strengthening motivation to recover from cocaine and/or alcohol use, and on developing techniques to handle possible barriers to recovery. We seek to enroll 300 patients in the study.

NCT ID: NCT00218608 Completed - Clinical trials for Opioid-Related Disorders

Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone

Start date: April 2001
Phase: Phase 2
Study type: Interventional

Cocaine is an extremely addictive stimulant drug that directly affects the brain. It is used in several different forms and can be snorted, smoked, or injected to achieve the desired effect. Cocaine users are at risk for many health problems, both directly and indirectly related to the effects of cocaine. Disulfiram, a drug used to treat chronic alcoholism, may be effective in reducing cocaine use. This study will evaluate the effectiveness of three different doses of disulfiram in treating cocaine dependence in opioid- and cocaine-dependent individuals maintained on methadone.

NCT ID: NCT00218569 Completed - Alcohol Dependence Clinical Trials

Combined Treatment for Cocaine-Alcohol Dependence - 1

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine whether Naltrexone and cognitive behavioral therapy can be helpful in patients who want to stop using cocaine and alcohol.

NCT ID: NCT00218543 Completed - Clinical trials for Attention Deficit Disorder With Hyperactivity

Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Atom
Start date: June 2004
Phase: Phase 2
Study type: Interventional

Studies have shown that individuals with attention deficit hyperactivity disorder (ADHD) are at greater risk for having a substance use disorder compared to people who do not have ADHD. Rates of cocaine abuse in adults with ADHD are significantly higher than they are in adults who do not have ADHD. Some clinicians suggest that adults with ADHD may abuse cocaine in order to self-medicate their ADHD symptoms. Atomoxetine is a drug that has been effective in treating ADHD. This study will evaluate the effectiveness of atomoxetine in reducing cocaine use in people with ADHD who abuse cocaine.

NCT ID: NCT00218491 Completed - Cocaine Dependence Clinical Trials

Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1

NAC
Start date: November 2005
Phase: Phase 2
Study type: Interventional

Currently, no effective drug treatment exists for cocaine dependence. Glutamate levels are disrupted with long-term cocaine use. N-acetyl cysteine (NAC) is a drug that is metabolized by the body to form cysteine, an active compound that normalizes glutamate levels. The purpose of this study is to determine the safety and effectiveness of NAC in treating cocaine dependent individuals.

NCT ID: NCT00218387 Completed - Cocaine Dependence Clinical Trials

Modafinil Combined With Cognitive Behavior Therapy to Treat Cocaine Addiction - 1

Start date: April 2004
Phase: Phase 2
Study type: Interventional

Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Modafinil, a medication that enhances mood, increases energy, and improves concentration, may be useful in preventing relapse among individuals with cocaine addiction. This study will evaluate the effectiveness of modafinil, in combination with cognitive behavior therapy (CBT), to prevent drug relapse among cocaine addicts.

NCT ID: NCT00218348 Completed - Clinical trials for Cocaine-Related Disorders

Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo

Start date: September 2003
Phase: Phase 2
Study type: Interventional

Dextro-amphetamine sulfate is a central nervous system stimulant that increases the release of the neurotransmitter dopamine in the brain. The purpose of this study is to further examine dose ranges of dextro-amphetamine sulfate as a treatment for cocaine dependence.

NCT ID: NCT00218257 Completed - Clinical trials for Cocaine-Related Disorders

Progesterone for the Treatment of Cocaine Dependence - 1

Start date: July 2002
Phase: N/A
Study type: Interventional

Past research has demonstrated that cocaine dependent women experience less severe responses to cocaine during the luteal phase of the menstrual cycle, when estrogen and progesterone concentrations are high. The purpose of this study is to determine whether administered progesterone reduces subjective and physiological responses to cocaine in cocaine dependent individuals.